[go: up one dir, main page]

MX2018008549A - Composicion farmaceutica que comprende derivado de quinolina o sal del mismo. - Google Patents

Composicion farmaceutica que comprende derivado de quinolina o sal del mismo.

Info

Publication number
MX2018008549A
MX2018008549A MX2018008549A MX2018008549A MX2018008549A MX 2018008549 A MX2018008549 A MX 2018008549A MX 2018008549 A MX2018008549 A MX 2018008549A MX 2018008549 A MX2018008549 A MX 2018008549A MX 2018008549 A MX2018008549 A MX 2018008549A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
salt
quinolina
same
includes derivative
Prior art date
Application number
MX2018008549A
Other languages
English (en)
Other versions
MX382054B (es
Inventor
Lu Yun
Zhang Xinhua
Wang Chenyang
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2018008549A publication Critical patent/MX2018008549A/es
Publication of MX382054B publication Critical patent/MX382054B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona una composición farmacéutica que comprende un derivado de quinolina o una sal del mismo. Específicamente, la invención proporciona una composición farmacéutica que comprende un (R, E)-N-(4-(3-cloro-4-(piridina-2-i lmetoxi)fenilamino) -3-ciano-7-etoxiquinolina-6-ilo)-3-(1-metilpir rolidina-2-il)-propeneamida o una sal farmacéuticamente aceptable de la misma, una polivinilpirrolidona reticulada y al menos un excipiente farmacéuticamente aceptable. La composición farmacéutica tiene una propiedad de disolución rápida.
MX2018008549A 2016-01-27 2017-01-23 Composición farmacéutica que comprende derivado de quinolina o sal del mismo. MX382054B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610056739 2016-01-27
PCT/CN2017/072155 WO2017129087A1 (zh) 2016-01-27 2017-01-23 一种含有喹啉衍生物或其盐的药物组合物

Publications (2)

Publication Number Publication Date
MX2018008549A true MX2018008549A (es) 2018-09-19
MX382054B MX382054B (es) 2025-03-13

Family

ID=59397432

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008549A MX382054B (es) 2016-01-27 2017-01-23 Composición farmacéutica que comprende derivado de quinolina o sal del mismo.

Country Status (13)

Country Link
US (1) US11065241B2 (es)
EP (1) EP3378478B1 (es)
JP (1) JP6864691B2 (es)
KR (1) KR102720987B1 (es)
CN (2) CN108354909B (es)
AU (1) AU2017212452B2 (es)
BR (1) BR112018014559A2 (es)
CA (1) CA3011525C (es)
HK (1) HK1243358B (es)
MX (1) MX382054B (es)
RU (1) RU2743014C2 (es)
TW (1) TWI726978B (es)
WO (1) WO2017129087A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3079916A1 (en) * 2017-10-24 2019-05-02 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing quinoline derivative

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101824029A (zh) * 2009-03-05 2010-09-08 厦门艾德生物医药科技有限公司 酪氨酸激酶不可逆抑制剂、其药物组合物及其用途
CN102020639A (zh) 2009-09-14 2011-04-20 上海恒瑞医药有限公司 6-氨基喹唑啉或3-氰基喹啉类衍生物、其制备方法及其在医药上的应用
CN102675287A (zh) * 2011-03-11 2012-09-19 江苏恒瑞医药股份有限公司 (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用
CN103987700B (zh) * 2012-03-09 2016-08-31 江苏豪森药业集团有限公司 4-喹唑啉胺类衍生物及其用途
US9296753B2 (en) * 2012-06-04 2016-03-29 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
CN103539783A (zh) * 2012-07-12 2014-01-29 江苏恒瑞医药股份有限公司 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法

Also Published As

Publication number Publication date
EP3378478B1 (en) 2022-05-11
CA3011525C (en) 2023-12-05
CN108354909A (zh) 2018-08-03
US20200138803A1 (en) 2020-05-07
RU2018128411A (ru) 2020-02-27
TWI726978B (zh) 2021-05-11
AU2017212452A1 (en) 2018-08-02
KR20180103089A (ko) 2018-09-18
AU2017212452B2 (en) 2022-04-14
JP2019503366A (ja) 2019-02-07
HK1243358B (zh) 2019-08-16
RU2018128411A3 (es) 2020-04-30
MX382054B (es) 2025-03-13
CN107405344B (zh) 2018-08-14
US11065241B2 (en) 2021-07-20
CA3011525A1 (en) 2017-08-03
CN107405344A (zh) 2017-11-28
CN108354909B (zh) 2021-05-14
EP3378478A4 (en) 2018-12-26
RU2743014C2 (ru) 2021-02-12
WO2017129087A1 (zh) 2017-08-03
BR112018014559A2 (pt) 2018-12-11
KR102720987B1 (ko) 2024-10-24
EP3378478A1 (en) 2018-09-26
JP6864691B2 (ja) 2021-04-28
TW201726135A (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
CY1124652T1 (el) Παραγωγα 1η-ινδαζολο-3-καρβοξαμιδιου και σχετικες ενωσεις ως αναστολεις παραγοντα d για τη θεραπεια νοσων που χαρακτηριζονται απο μη φυσιολογικη δραστηριοτητα συστηματος συμπληρωματος, οπως π.χ. ανοσολογικες διαταραχες
CY1124389T1 (el) Υποκατεστημενα 3-αζαδικυκλο[3.1.0]εξανια ως αναστολεις κετοεξωκινασης
CY1124432T1 (el) Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη
CY1124548T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
CL2018002727A1 (es) Medicina obtenida mediante la combinación de agonista fxr y arb
CY1119645T1 (el) Τριπεπτιδικοι αναστολεις πρωτεασης εποξειδικης κετονης
MX392213B (es) Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano.
MY190835A (en) Bicyclic heterrocyclic derivatives as bromodomain inhibitors
MX374412B (es) Una composición que comprende un inhibidor de pde3/pde4 o una sal de adición del mismo y un antagonista del receptor muscarínico.
JOP20190108B1 (ar) تركيبات صيدلانية
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
HUE061963T2 (hu) Karbamid-vegyületek és készítmények mint SMARCA2/BRM-ATPáz gátlók
BR112017023225A2 (pt) inibidor de proteína cinase
IL283539A (en) 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same
MX2018006799A (es) Composicion farmaceutica.
CY1121345T1 (el) Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης
EP3880671C0 (en) NOVEL COMPOUND USED AS A PROTEIN KINASE INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
BR112017028137A2 (pt) agente terapêutico para fibrose
EA201890944A1 (ru) Фармацевтические композиции нилотиниба гидрохлорида
CL2019002808A1 (es) Métodos para prevenir o tratar enfermedades oftálmicas.
DK4023651T3 (da) Optisk aktivt pyranochromenylphenolderivat og farmaceutisk sammensætning, der omfatter samme
EP3539978C0 (en) NKX3.2 FRAGMENT AND PHARMACEUTICAL COMPOSITION COMPRISING IT AS AN ACTIVE INGREDIENT
MX2018008549A (es) Composicion farmaceutica que comprende derivado de quinolina o sal del mismo.